
In a 28-page written submission to the UK’s Competition and Markets Authority (CMA) that was published Monday, January 10, the semiconductor heavyweights Nvidia, Softbank, and Arm outlined why their deal should be approved, reported CNBC.
The deal, which is set to miss the target deadline of March 2022, is being closely scrutinized by regulators in the US, the UK, Europe, and China, who are concerned that it could reduce competition. SoftBank, Nvidia, and Arm agreed to complete the transaction within 18 months of September 2020.
There’s a high chance that one or more of the regulators will block the deal altogether, according to Gartner analyst Alan Priestley and other investors.
Related: FTC Sues To Block Nvidia’s $40B Deal For UK’s Arm
Widely viewed as a the jewel in the crown of the UK tech industry, Arm was spun out of an early computing company called Acorn Computers in 1990. The company’s energy-efficient chip designs are used in 95% of the world’s smartphones and 95% of the chips designed in China. The company, bought by SoftBank in 2016 for £24 billion (US$32 billion), licenses its chip designs to more than 500 companies who use them to make their own semiconductors.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas